WO2023166130A1 - Procédé de sélection de cellules clonales exprimant des molécules de liaison multispécifiques assemblées correctement - Google Patents

Procédé de sélection de cellules clonales exprimant des molécules de liaison multispécifiques assemblées correctement Download PDF

Info

Publication number
WO2023166130A1
WO2023166130A1 PCT/EP2023/055345 EP2023055345W WO2023166130A1 WO 2023166130 A1 WO2023166130 A1 WO 2023166130A1 EP 2023055345 W EP2023055345 W EP 2023055345W WO 2023166130 A1 WO2023166130 A1 WO 2023166130A1
Authority
WO
WIPO (PCT)
Prior art keywords
host cells
polypeptides
specific binding
polypeptide
binding site
Prior art date
Application number
PCT/EP2023/055345
Other languages
English (en)
Inventor
Ramón GOMEZ DE LA CUESTA
Weronika FIC
Amit Sharma
Original Assignee
Lonza Biologics Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics Plc. filed Critical Lonza Biologics Plc.
Publication of WO2023166130A1 publication Critical patent/WO2023166130A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Definitions

  • the present invention relates to methods for selecting cells that express multi-specific binding molecules, such as antibodies, and in particular bispecific antibodies, with high levels of correctly assembled protein.
  • Bispecific antibodies have shown much promise as a therapeutic approach: bispecific antibodies are entering clinical studies in record numbers, with most developed for cancer.
  • Such molecules unlike naturally occurring IgG molecules, contain at least 2 and usually at least 4 different chains (e.g., two heavy and two light chains). Therefore, there are a number of different permutations for assembly of the complete product, whereas for naturally occurring IgG molecules there is only one.
  • Multi-specific therapeutic molecules bind to at least two different antigens on the cancer cell as well as recruiting at least one effector cell (NK- or T-cell) to the tumour site.
  • Protein engineering tools employed to generate such complex molecules therefore involve complex design of multiple polypeptide chains that need to come together in the correct ratio to form a fully functional multi-specific molecule. This poses a significant challenge to the cellular machinery.
  • a method to determine the correct assembly of a tri-specific molecule for example: an IgG molecule that binds to HER1 (Antigen 1), HER2 (Antigen 2) on the cancer cell, and recruits a T-cell through an scFv that binds to CD3 (Antigen 3) on the T-cell receptor, using for example an In-Beacon assay and a plate-based assay.
  • a tri-specific molecule for example: an IgG molecule that binds to HER1 (Antigen 1), HER2 (Antigen 2) on the cancer cell, and recruits a T-cell through an scFv that binds to CD3 (Antigen 3) on the T-cell receptor
  • the present invention provides a method that enables individual cell clones to be analysed in vitro whilst growing and secreting recombinant protein.
  • reagents that bind specifically to the correctly paired regions of the product different producing clones can be assessed and compared to enable selection of cells that efficiently produce improved ratios of correctly formed product to incorrectly formed product.
  • the present invention provides a method of selecting a cell for expression of a multi-specific binding molecule comprising the following steps:
  • step (d) selecting one or more host cells expressing a multi-specific binding molecule based on a comparison of the two levels measured in step (c).
  • the present invention provides a method of selecting a cell for expression of a multi-specific binding molecule comprising the following steps:
  • step (d) selecting one or more host cells expressing a multi-specific binding molecule based on a comparison of the two levels measured in step (c).
  • the invention relates to a method of selecting a cell for expression of a multi-specific binding molecule comprising the following steps:
  • step (d) selecting one or more host cells expressing a multi-specific binding molecule based on a comparison of the two levels measured in step (c).
  • the third and fourth polypeptides are the same.
  • the host cells comprise the same one or more nucleic acid sequences encoding the at least two or at least four polypeptides.
  • the multi-specific binding molecules are secreted by the host cells.
  • the multi-specific binding molecule is a multi-specific antibody or a bispecific antibody.
  • the first and/or second labelled reagent comprises a target antigen of the multi-specific binding molecule.
  • the labels for the first and second reagents are different.
  • the first and/or second labelled reagent is a fluorescently-labelled reagent.
  • the first and/or second labelled reagent is an anti-idiotypic antibody- fluorophore conjugate.
  • the host cells are mammalian cells.
  • the host cells are cultured in a volume of between about 0.3 nanoliters and about 500 microliters.
  • the host cells are cultured in a microplate or in a fluidic device.
  • the host cells are cultured in a microfluidic device, optionally wherein the microfluidic device comprises a microfluidic channel to which a plurality of sequestration pens are fluidically connected, optionally wherein the host cells are loaded into the microfluidic device such that a plurality of the sequestration pens are each loaded with one host cell.
  • the method further comprises incubating a host cell selected according to step (d) under conditions that allow for expression of the at least two different polypeptides and assembly into a multi-specific binding molecule, and isolating the multi-specific binding molecule.
  • the invention relates to a method of expressing in a host cell a multi-specific binding molecule, which method comprises incubating a host cell selected according to the method described herein under conditions that allow for expression of the at least two different polypeptides and assembly into a multi-specific binding molecule, and isolating the multi-specific binding molecule.
  • the invention relates to a multi-specific binding molecule prepared by the method of expressing in a host cell a multi-specific binding molecule described herein.
  • Figure 1 Diagram showing (A) an individual sequestration pen in a microfluidic device such as the Berkeley Lights Beacon as well as a representation of optoelectric positioning; and (B) a typical workflow using the Beacon to select cells.
  • the antibodies shown are as an example, labelled anti-idiotypic antibodies that bind to a correctly formed binding site in the multispecific antibodies of interest that are produced by the cell clones in each pen.
  • Figure 2 Normalized intensities of varying ratios of mAbs ‘spiked’ in null CCS (cell culture supernatant). Different ratios of monoclonal antibodies mAb1 and mAb2 were spiked into cell culture supernatant. mAb1 and mAb2 were immobilized in protein A-coated wells of a 96-well plate, washed and the ratio of binding sites determined by incubation with fluorescently labelled antigens specifically binding the binding sites of the monoclonal antibodies.
  • Figure 3 Normalized intensities of microplate plate assay to determine the heterogeneity of bispecific antibodies with different architectures.
  • Cell culture supernatant from host cells producing bispecific antibodies of two different architectures (Bs1 and Bs2) was added to protein A-coated wells of a 96-well plate, thereby immobilizing the bispecific antibodies.
  • Antibodies were washed and the ratio of binding sites determined by incubation with fluorescently labelled antigens specifically binding the individual binding sites of the bispecific antibodies.
  • the fluorescence intensity is determined and normalized for each of the reagents (i.e., labelled antigens), to obtain an intensity score for each reagent and well.
  • a pairing score may be calculated by dividing the lowest intensity score by the highest intensity score for each well.
  • a well comprising only perfectly assembled bispecific antibodies will yield identical intensity scores for each reagent and therefore a pairing score of 1 (i.e., 100%). Mispairing will result in different intensity scores for each reagent and thus pairing scores below 1 , e.g., 0.95, 0.9 or 0.8.
  • the present invention provides a method of selecting a cell for expression of a multi-specific binding molecule comprising the following steps:
  • step (d) selecting one or more host cells expressing a multi-specific binding molecule based on a comparison of the two levels measured in step (c).
  • the present invention provides a method of selecting a cell for expression of a multi-specific binding molecule comprising the following steps:
  • step (d) selecting one or more host cells expressing a multi-specific binding molecule based on a comparison of the two levels measured in step (c).
  • the present invention provides a method of selecting a cell for expression of a multi-specific binding molecule comprising the following steps:
  • step (d) selecting one or more host cells expressing a multi-specific binding molecule based on a comparison of the two levels measured in step (c).
  • the first, second, third and fourth polypeptides may be referred to herein as polypeptides (i), (ii), (iii) and (iv), respectively.
  • the methods described herein are for selecting a host cell for expression of a correctly assembled multi-specific binding molecule.
  • the multi-specific binding molecule when correctly assembled, comprises one copy of each, the first and the second polypeptide, or one copy of each, the first, second, third and fourth polypeptide.
  • the at least two polypeptides or the at least four polypeptides are heterologous polypeptides.
  • a heterologous polypeptide is a polypeptide that is not natively expressed by the host cells, i.e. , a polypeptide that is derived from a different organism or cell type as compared to the host cells.
  • the third and fourth polypeptides are the same.
  • the target molecule to which the first binding site (formed by the first polypeptide or by the first and third polypeptides) binds is different to the target molecule to which the second binding site (formed by the second polypeptide or by the second and fourth polypeptides) binds.
  • the first binding site is a first immunoglobulin antigen binding region
  • the second binding site is a second immunoglobulin antigen binding region.
  • the at least two polypeptides each comprise three immunoglobulin complementarity determining regions (CDRs).
  • the first polypeptide may comprise a first set of three CDRs
  • the second polypeptide may comprise a second set of three CDRs.
  • the third polypeptide may comprise a third set of three CDRs
  • the fourth polypeptide may comprise a fourth set of three CDRs.
  • the first polypeptide comprises a first immunoglobulin heavy chain Fab region and the second polypeptide comprises a second immunoglobulin heavy chain Fab region.
  • the third polypeptide comprises a first immunoglobulin light chain Fab region and the fourth polypeptide comprises a second immunoglobulin light chain Fab region.
  • the first polypeptide comprises a first immunoglobulin heavy chain Fab region
  • the second polypeptide comprises a second immunoglobulin heavy chain Fab region
  • the third polypeptide comprises a first immunoglobulin light chain Fab region
  • the fourth polypeptide comprises a second immunoglobulin light chain Fab region.
  • At least one of the polypeptides comprises a signal peptide that leads to secretion of the multi-specific binding molecule from the host cells.
  • the multi-specific binding molecules are secreted by the host cells.
  • the multi-specific binding molecule is a multi-specific antibody or a bispecific antibody.
  • the first and second labelled reagent generally comprise a moiety that binds selectively to the first or second binding site, respectively, and a label. Selective binding of the first and second labelled reagent to the first or second binding site, respectively, generally requires correct assembly of the first or second binding site after expression of the polypeptides by the host cells.
  • the first and/or second labelled reagent comprises a target antigen of the multi-specific binding molecule, i.e. , the labelled reagents comprise the target molecule to which the first and the second binding site bind, or a fragment thereof.
  • the first and second labelled reagents comprise the target antigens of the multi-specific binding molecule.
  • the first and/or second labelled reagent is an anti-idiotypic antibody or antibody fragment (e.g., Fab or scFv molecules).
  • the first and second labelled reagents are anti-idiotypic antibodies or antibody fragments.
  • the labels for the first and second reagents are different.
  • the first and/or second labelled reagent is a fluorescently-labelled reagent.
  • the first and second labelled reagents are fluorescently-labelled reagents.
  • the first and/or second labelled reagent is an anti-idiotypic antibody- fluorophore conjugate.
  • the first and second labelled reagents are anti-idiotypic antibody-fluorophore conjugates.
  • the host cells are mammalian cells.
  • the host cells are cultured in a volume of between about 0.3 nanoliters (nL) and about 500 microliters (pL).
  • the cells are cultured in a volume of between about 0.4 nanoliters and about 250 microliters, more preferably between about 0.5 nanoliters and about 200 microliters.
  • the host cells are cultured in a microplate.
  • the microfluidic device comprises a microfluidic channel to which a plurality of sequestration pens are fluidically connected.
  • the host cells may be loaded into the microfluidic device such that a plurality of the sequestration pens are each loaded with one host cell.
  • a multi-specific binding molecule in the context of the present invention is a complex of two or more different polypeptide components that comprises at least two different binding sites which bind to target molecules.
  • the present invention is applicable to molecular complexes where there are multiple components which could assemble in different ways with one another, and it is desired to maximise the correct assembly of the molecule.
  • a clone is a host cell or a host cell population that is genetically homogenous.
  • Each polypeptide component comprises a binding region for a target molecule of interest.
  • the binding region of each component can pair with a binding region of another component to form a binding site for the target molecule.
  • the overall molecular complex has at least two different binding sites, which may be for a different site on the same target molecule or, more commonly, two different target molecules.
  • target molecules include cell surface molecules, such as receptors, spike proteins, extracellular proteins or any antigen protein.
  • the first target molecule (Antigen 1) of the multi-specific binding molecule is HER1 and the second target molecule (Antigen 2) of the multi-specific binding molecule is HER2 on the cancer cell.
  • the multi-specific binding molecule recruits a T-cell through an scFv that binds to CD3 (Antigen 3) on the T-cell receptor.
  • the method of selecting a cell for expression of a multispecific binding molecule further comprises incubating a host cell selected as described herein under conditions that allow for expression of the at least two different polypeptides and assembly into a multi-specific binding molecule, and isolating the multi-specific binding molecule.
  • the present invention provides a method of expressing in a host cell a multi-specific binding molecule, which method comprises incubating a host cell selected according to a method described herein under conditions that allow for expression of the at least two different polypeptides and assembly into a multi-specific binding molecule, and isolating the multi-specific binding molecule.
  • the present invention provides a multi-specific binding molecule prepared by a method of selecting a cell for expression of a multi-specific binding molecule or a method of expressing in a host cell a multi-specific binding molecule described herein.
  • polypeptides are single-domain antibodies.
  • the multi-specific binding molecule is a multi-specific antibody or a bispecific antibody.
  • the multi-specific binding molecule is an IgG-like bispecific antibody such as a DVD-IgG, IgG-scFv-scFv, scFv4, IgG-Fab, IgG-VH/VL or DVI- IgG.
  • the target molecule to which the first binding site (formed by the first polypeptide or by the first and third polypeptides) binds is different to the target molecule to which the second binding site (formed by the second polypeptide or by the second and fourth polypeptides) binds.
  • a typical example of the multi-specific binding molecule is a bispecific antibody which commonly comprises two different heavy chains and two different light chains such that, by contrast to a naturally-occurring IgG antibody, has two different antigen binding regions.
  • a common light chain is used and so there are only three different chains, i.e., the third and fourth polypeptides may comprise an immunoglobulin light chain Fab region and may be identical.
  • the polypeptide chains may comprise immunoglobulin antigen binding regions (i.e., the complementarity determining regions (CDRs)) optionally with some associated immunoglobulin constant region sequences.
  • the polypeptide chains may comprise the Fab regions of an immunoglobulin without any Fc regions - these may be omitted or substituted with alternative sequences that provide for pairing such as other types of polypeptides that dimerize (e.g., a leucine zipper).
  • Naturally occurring immunoglobulins generally have 3 CDRs on each polypeptide chain such that 6 CDRs form an antigen binding site.
  • the immunoglobulin antigen binding region of each of the polypeptides typically includes 3 CDRs.
  • the polypeptide chains are complete, or substantially complete immunoglobulin chains, such as immunoglobulin light chains or heavy chains.
  • the sequences may be engineered to enhance correct heavy chain to heavy chain pairing by substitutions in the Fc region, e.g., mutations that create cysteine residues to provide for disulphide linkages; “knobs-in-holes” type mutations such as the WSAV approach; and/or substitutions that direct electrostatic interactions (electrostatic steering).
  • sequences may be engineered to enhance correct heavy chain to light chain pairing by substitutions in the Fab region (constant or variable domains), e.g., mutations that create cysteine residues to provide for disulphide linkages; electrostatic steering; and/or domain swapping, such as the CrossMAbs approach.
  • IgG-like bispecific antibodies such as DVD-IgG, IgG-scFv-scFv, scFv4, IgG-Fab, IgG-VH/VL, DVI-IgG; and fusions such as dock and lock (see Bratt et al., 2017, BioProcess International 15(11): 36-42).
  • Any suitable host cell type may be used in the methods of the invention which can be genetically manipulated to express and secrete multi-specific binding molecules.
  • Preferred host cells are those that can be used to express the multi-specific binding molecules on a large scale, for commercial production of the multi-specific molecule.
  • the host cell is not a bacterial cell.
  • the host cell is a eukaryotic cell, for example mammalian, yeast or insect cell. In one embodiment, the host cell is a mammalian cell.
  • Example species from which host cell can be derived include human, mouse, rat, Chinese hamster, Syrian hamster, monkey, ape, dog, horse, ferret, and cat.
  • the mammalian host cell is a Chinese hamster ovary (CHO) cell.
  • the host cell is a CHO-K1 cell, a CHOK1SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHO-S, a CHO GS knock-out cell, a CHOK1SV FUT8 knock-out cell, a CHOZN, ora CHO-derived cell.
  • the CHO GS knock-out cell e.g., GSKO cell
  • the CHO FLIT8 knockout cell is, for example, the Potelligent® CHOK1SV FLIT8 knock-out (Lonza Biologies, pic).
  • mammalian host cells include HeLa, MDCK, HEK293, HEK293T, HT1080, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK (baby hamster kidney), VERO, SP2/0, NSO, YB2/0, YO, EB66, C127 and COS (e.g., COS1 and COS7).
  • the host cell is a cell other than a mammalian cell, such as avian, fish, insect, plant, fungus, or yeast cell.
  • the eukaryotic cell is a lower eukaryotic cell such as, e.g., a yeast cell (e.g., Pichia genus (e.g., Pichia pastoris, Pichia methanolica, Pichia kluyveri, and Pichia angusta), Komagataella genus, Saccharomyces genus (e.g. Saccharomyces cerevisae, Saccharomyces kluyveri, Saccharomyces uvarum), or Kluyveromyces genus (e.g. Kluyveromyces lactis, Kluyveromyces marxianus).
  • the eukaryotic cell is of the species Pichia pastoris. Examples for Pichia pastoris strains include but are not limited to X33, GS115, KM71 , KM71 H, and CBS7435.
  • the eukaryotic cell is an insect cell (e.g., Sf9, MimicTM Sf9, Sf21 , High FiveTM (BT1-TN-5B1-4), or BT1-Ea88 cells).
  • insect cell e.g., Sf9, MimicTM Sf9, Sf21 , High FiveTM (BT1-TN-5B1-4), or BT1-Ea88 cells.
  • Suitable host cells are commercially available, for example, from culture collections such as the DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany) or the American Type Culture Collection (ATCC). Population of Host Cells Transformed with Nucleic Acid Sequences Expressing Multispecific Binding Molecules
  • Nucleic acid sequences encoding the different components of the multi-specific binding molecules can be introduced into populations of host cells using techniques well known in the art.
  • the sequences encoding the constituent polypeptide chains, operably linked to regulatory control elements that drive expression of the polypeptides in the host cells are typically present in one or more nucleic acid vectors.
  • One or more of the polypeptides will also typically include a signal sequence that directs secretion of the polypeptide from the host.
  • the vectors typically include one or more selectable markers to enable selection of host cells that have taken up the nucleic acid vectors. Examples of selectable markers include dhfr and amino acid auxotrophy-based markers such as glutamine synthetase (GS).
  • a population of cells may be generated wherein a plurality of the cells comprise one or more nucleic acid sequences encoding (i) a first polypeptide comprising a first immunoglobulin antigen binding region, such as an immunoglobulin CDR; (ii) a second polypeptide comprising a second immunoglobulin antigen binding region, such as an immunoglobulin CDR; (iii) a third polypeptide comprising a third immunoglobulin antigen binding region, such as an immunoglobulin CDR; and (iv) a fourth polypeptide comprising a fourth immunoglobulin antigen binding region, such as an immunoglobulin CDR, wherein the first and third immunoglobulin antigen binding regions (e.g., CDRs) together form a first antigen binding site and the second and fourth immunoglobulin antigen binding regions (e.g., CDRs) together form a second antigen binding site different to the
  • the purpose of the selection process is to identify and develop further particular clones that produce high levels of correctly paired molecular complexes of interest (e.g., multi-specific binding molecules).
  • Various genetic factors may mean that in a population of clones that have been transformed with the same sequences, not all clones behave in the same manner.
  • the host cells within the population of host cells used in the methods according to the invention comprise the same one or more nucleic acid sequences encoding the polypeptides described herein.
  • the host cells used in the methods according to the invention comprise the same one or more nucleic acid sequences encoding the at least two polypeptides.
  • the host cells used in the methods according to the invention comprise the same one or more nucleic acid sequences encoding the at least four polypeptides.
  • the host cells have all been transformed with the same one or more nucleic acid sequences.
  • providing a population of host cells comprising one or more nucleic acid sequences comprises introduction of the one or more nucleic acid sequences into the host cells.
  • providing a population of host cells comprising one or more nucleic acid sequences further comprises selecting host cells for successful introduction of the one or more nucleic acid sequences into the host cells.
  • the variation comes from the host cells themselves.
  • the population of cells that is subject to testing and selection contains the same sequences encoding the first, second, and, where applicable, third and fourth polypeptides. Due to transformation efficiencies, it is possible that not every cell in the population contains all of the sequences but those cells would in any case not be of interest.
  • the CDRs may be part of an immunoglobulin Fab region and accordingly the plurality of the cells may comprise (i) a first polypeptide comprising a first immunoglobulin heavy chain Fab region; (ii) a second polypeptide comprising a second immunoglobulin heavy chain Fab region; (iii) a third polypeptide comprising a first immunoglobulin light chain Fab region; and (iv) a fourth polypeptide comprising a second immunoglobulin light chain Fab region.
  • the first immunoglobulin heavy chain Fab region and the first immunoglobulin light chain Fab region together form a first immunoglobulin antigen binding region; and the second immunoglobulin heavy chain Fab region and the second immunoglobulin light chain Fab region together form a second immunoglobulin antigen binding region different to the first immunoglobulin antigen binding region.
  • some approaches include a common chain such that there are 3 different polypeptides rather than 4 or more. Accordingly, one of the polypeptides (i) to (iv) may be identical to one or the others.
  • the third and the fourth polypeptide may be identical and there are in reality three different polypeptides: a first, a second and a third polypeptide such that the first polypeptide pairs with the third polypeptide for the first antigen binding site and the second polypeptide also pairs with the third polypeptide for the second antigen binding site.
  • polypeptides may also comprise Fc regions to form full length heavy and light chains.
  • polypeptides may have been modified to promote heavy chain-heavy chain pairing and/or heavy light chain pairing.
  • the host cells to be screened for expression of a correctly assembled multi-specific binding molecule according to the methods of the invention may be cultured in various suitable formats or devices known to the skilled artisan, including microplates or fluidic devices (e.g., in a microfluidic device or in a nanofluidic device).
  • Selection of one or more cells expressing a multi-specific binding molecule based on a comparison of the levels of labelled reagents bound to their respective binding sites is generally facilitated by loading individual cells into compartments of a device used for culturing of the cells (e.g., individual well of a microplate or sequestration pen of a fluidic device), such that, after clonal expansion, each compartment comprises a population of cells resulting from clonal expansion of a single cell.
  • the host cells are loaded into compartments of a device (e.g., a microplate or a fluidic device) used for culturing of the cells, such that a plurality of the compartments are each loaded with one host cell.
  • a compartment may be a well of a microplate or a sequestration pen of a fluidic device.
  • the host cells are clonally expanded to obtain a plurality of host cell populations, each of which is genetically homogenous.
  • providing a population of host cells comprises clonally expanding the host cells to obtain a plurality of host cell populations, each of which is genetically homogenous.
  • the host cells are loaded into compartments of a device (e.g., a microplate or a fluidic device) used for culturing of the cells, such that a plurality of the compartments are each loaded with one host cell, wherein the host cells are subsequently clonally expanded to obtain a plurality of host cell populations, each of which is genetically homogenous.
  • the host cells are cultured in a microplate (also referred to as multiwell plate or microtiter plate), e.g., a 24-well plate, a 48-well plate, 96-well plate, a 384-well plate or a 1536-well plate.
  • a microplate also referred to as multiwell plate or microtiter plate
  • the host cells are cultured in a 96-well plate or a 384-well plate, more preferably in a 96-well plate.
  • the host cells are cultured in a fluidic device (e.g., in a microfluidic device or in a nanofluidic device).
  • a population of cells is introduced into a fluidic device (such as a microfluidic device or a nanofluidic device) which comprises a channel (such as a microchannel or a nanochannel) to which a plurality of sequestration pens are fluidically connected.
  • the fluidic device comprises a substrate and the channel and pens are part of a fluidic structure which is disposed on a surface of the substrate. Cells suspended in a liquid medium can flow along the channel and pass the sequestration pens.
  • the device is configured to enable individual cells to be loaded into a sequestration pen so that each sequestration pen contains only one cell, and also to enable the cells within a particular sequestration pen to be released into the channel and collected.
  • the pens may be between about 0.3 nanoliters and about 500 microliters in volume, for example between about 0.3 and about 10 nL in volume for a microfluidic device.
  • the sequestration pens may comprise a fluidic isolation structure comprising an isolation region having a single opening and a connection region fluidically connecting said isolation region to the channel, the connection region comprising a proximal opening into the channels.
  • the substrate may be tilted at a small angle from the horizontal so that cells settle to the bottom of the sequestration pens and away from the narrow single opening into the channel.
  • OEP OptoElectricPositioning
  • Berkeley Lights Inc. Emeryville, CA Beacon system
  • lacis Light-activated cell identification and sorting
  • OEP is based on a microfluidic device which includes a transparent electrode on a silicon substrate with a fluidic chamber sandwiched between the two.
  • the substrate is fabricated with an array of photosensitive transistors. When focused light hits the transistors and a voltage is applied, a non-uniform electric field is generated. This imparts a negative dielectrophoresis (DEP) force that repels particles (including cells) using light-induced OEP ( Figure 1a). In the absence of targeted light, no force is generated. When light is shined on the photoconductive material, DEP force is generated and cells trapped inside light “cages” can be moved across the chamber.
  • DEP dielectrophoresis
  • sequestration pens are integrated into the chip to isolate cells from each other, enabling on-chip culture of well-separated colonies emanating from single cells.
  • selected clones can be exported off the microfluidic device for further processing.
  • the export is the reverse of the import process, where desired cells are moved using OEP from single sequestration pens into the main channel and flushed, for example, into a target well of a 96-well plate positioned inside a CO2- and temperature-controlled incubator.
  • the microfluidic device may, as per any manufacturer’s instructions, be pre-wetted with a suitable wetting solution that creates an environment compatible with the host cells and allows for good penning efficiency.
  • the device can then be primed with cell culture media suitable for the growth of the host cells and protein expression.
  • the cells Once cells have been loaded into a suitable device (e.g., microplate or fluidic device) and positioned into individual compartments (e.g., wells or sequestration pens), the cells are incubated to allow for cell growth and clonal expansion, as well as the production of the multispecific binding molecules. Monitoring of the different compartments can be used to ensure monoclonality in each compartment and also to ensure that the cells do not overfill the compartments prior to analysis of the multi-specific binding molecules.
  • a suitable device e.g., microplate or fluidic device
  • compartments e.g., wells or sequestration pens
  • the reagents comprise the corresponding target antigen for the binding sites, e.g., the target molecule or a fragment thereof.
  • the reagents are anti-idiotypic antibodies, including fragments thereof such as Fab, scFv molecules, specific to one of the correctly formed binding sites in the multi-specific molecule.
  • Other reagents include aptamers - oligonucleotide or peptide molecules that have the requisite binding specificity.
  • the binding molecules each need to be specific for the different binding sites so that binding can be distinguished.
  • the reagents are typically labelled with a detectable label to enable binding of the reagent to its target to be measured in situ in the device.
  • the label is a chemiluminescent label.
  • the label is a fluorescent label, such as a fluorophore or a fluorescent protein.
  • the detectable label is fluorescein or a derivative thereof (e.g., fluorescein isothiocyanate).
  • Exemplary fluorescent proteins are blue fluorescent proteins such as BFP and mTagBFP, cyan fluorescent proteins such as ECFP and TagCFP, green fluorescent proteins such as EGFP and ZsGreen, yellow fluorescent proteins such as EYFP and ZsYellow, red fluorescent proteins such as mRFP and mCherry, far-red proteins such as E2-Crimson.
  • blue fluorescent proteins such as BFP and mTagBFP
  • cyan fluorescent proteins such as ECFP and TagCFP
  • green fluorescent proteins such as EGFP and ZsGreen
  • yellow fluorescent proteins such as EYFP and ZsYellow
  • red fluorescent proteins such as mRFP and mCherry
  • far-red proteins such as E2-Crimson.
  • Each different reagent may be labelled with the same or a different detectable label.
  • each different reagent is labelled with a different detectable label.
  • Each reagent can be introduced into the device separately or at the same time, (which may depend on whether different labels are used as well as the ability of the imaging system to distinguish between different labels, such as different fluorescent (or chemiluminescent) signals, to enable simultaneous measurement).
  • the first reagent is introduced into the device such that it is able to enter the compartments (e.g., wells or sequestration pens) and contact the multi-specific molecule produced by the host cells in the compartment.
  • the reagent is present in the compartments for a period of time to provide sufficient binding to the multi-specific molecule (e.g., 45 to 60 minutes).
  • a suitable washing step if required, the binding of the first reagent to the first binding site in the molecule is determined, e.g., by fluorescent imaging of the device.
  • a wash step is then used to remove the first reagent and the process is repeated with the second reagent and so on.
  • the extent of binding of the first and second reagents is determined, e.g., using image analysis algorithms or scripts. This can be used to determine an intensity score (e.g., a normalized signal intensity) for each compartment (e.g., well or sequestration pen) for each reagent, adjusted as necessary to actual binding amounts depending on the performance of the labels used so that an accurate comparison of the intensity score for the different reagents can be made.
  • an intensity score e.g., a normalized signal intensity
  • compartment e.g., well or sequestration pen
  • the intensity score is determined by normalizing each level (e.g., signal intensity) of first labelled reagent and second labelled reagent to a standard.
  • the standard is a titration curve for each labelled reagent across the relevant concentration range.
  • the standard is a sample representative of a correctly assembled multi-specific binding molecule (e.g., a purified correctly assembled multi-specific binding molecule).
  • an individual standard is used for each labelled reagent, wherein each standard is a sample representative of correct assembly of the binding site that is selectively bound by the respective labelled reagent.
  • the level measured for the first labelled reagent is normalized using a standard which is a sample representative of correct assembly of the first binding site that is selectively bound by the first labelled reagent and the level measured for the second labelled reagent is normalized using a standard which is a sample representative of correct assembly of the second binding site that is selectively bound by the second labelled reagent.
  • the intensity scores for each reagent are then compared to obtain a pairing score, e.g., a percentage obtained by dividing the lowest intensity score by the highest intensity score for each pen.
  • a similar score e.g., greater than or equal to 90 or 95%, indicates high levels of correctly paired chains since similar amounts of correctly formed first and second binding sites in the multi-specific molecule are present in the compartment (e.g., well or sequestration pen). Expressed in another way, if the intensities are within +/- 20%, such as +/- 10% or +/- 5% of each other, then this would be considered a similar score.
  • levels of first labelled reagent and second labelled reagent bound to their respective binding sites that are within +/- 20% of each other (i.e., have intensity scores within +/- 20% of each other), preferably within +/- 10% of each other and most preferably within +/- 5% of each other indicate correctly-paired multi-specific binding molecules (i.e., multi-specific binding molecules comprising both a first binding site for a target molecule, and a second binding site for a target molecule).
  • selecting one or more host cells expressing a multi-specific binding molecule based on a comparison of the two levels (e.g., signal intensities) measured for the first labelled reagent and the second labelled reagent bound to their respective binding sites comprises selecting one or more host cells according to the level of correctly assembled multispecific binding molecule.
  • selecting one or more host cells expressing a multispecific binding molecule involves ranking host cells according to the level (e.g., signal intensity) ratio of the first labelled reagent and second labelled reagent. Host cells with a level (e.g., signal intensity) ratio closer to 1 are generally preferred in this process.
  • one or more host cells are selected according to their pairing score(s), e.g., one or more host cells are selected that have been determined to exhibit the highest pairing score(s).
  • the pairing score is obtained by comparing the level (e.g., intensity scores) of the first labelled reagent and the second labelled reagent.
  • cells in particular compartments are scored for productivity (total levels of multispecific molecule production) since it is advantageous for industrial production for the cells to be able to produce high titers of the product of interest.
  • the scoring may be a relative score between the various clones.
  • the Beacon system provides SpotlightTM Human Fc and kappa light chain assays. These are fluorophores that bind to the Fc and/or the kappa light chain constant region and give a fluorescence signal directly proportional to the amount of antibody expressed in that particular clone.
  • a “score” value is created by measuring the change in fluorescence in the or close to the neck of the pen in the (what they call diffusion gradient assay). A higher slope value means higher titre.
  • the maximum score is normalized to 100 and the minimum to 0. The values in between are the percent of the total and the score is calculated from these values.
  • the rQp is the relative production per cell of the last DiGr assay, i.e., the score divided by the number of cells.
  • the relative score may be normalized to a standard, e.g., normalized to the clone with the highest absolute productivity.
  • the signal e.g., fluorescent signal
  • the clone possessing the highest productivity is thus assigned a productivity of 100% and a clone possessing a lower productivity would be assigned a corresponding lower value (e.g., 90%, 70%, 50%, etc.).
  • clones that meet the threshold for correct pairing, and typically the threshold for productivity can then be exported from the device, e.g., into 96-well plates, for further growth. Typically, selected clones are then further assessed to identify the highest producing clones (high Qp).
  • Clones may optionally be subject to further analysis to confirm the high levels of correct pairing. For example, assessment of purified molecule by limited digestion (e.g., with Lys-C) and mass spectroscopy (LC-MS) can be used to check for quantitate in more detail the levels and configuration of non-correctly paired variants.
  • assessment of purified molecule by limited digestion e.g., with Lys-C
  • mass spectroscopy LC-MS
  • Selected clones can then be used to establish stable cell lines for use in manufacturing recombinant multi-specific binding molecules of interest, for example at a scale of greater than 500 g per batch, e.g., in a bioreactor having a volume of at least 10 L such as at least about 100, 200, 500, 1000 or 2000 L.
  • a bioreactor having a volume of at least 10 L such as at least about 100, 200, 500, 1000 or 2000 L.
  • Example 1 Determination of heterogeneity of mAbs using a microfluidic Beacon system
  • Fluorescence imaging of the chips is performed by the Beacon system, which can capture bright field and fluorescence images across multiple time points. Analysis of the image using a script results in assigning an “intensity score” to each NanoPenTM based on the gradient of intensity in a specific area of the NanoPen: the relative yield is measured this way. A script then compares the intensity scores for each NanoPen for fluorophore A and fluorophore B, and generates a “pairing score” based on similarity of the levels of bound fluorophore, the higher the score the more similar the levels of bound fluorophores A and B, and the higher percentage of correctly paired heterodimeric antibody that particular clone is producing. Software to analyse the fluorescence images also includes free software such as Imaged (available from the National Institutes of Health website), that measure intensity.
  • Imaged available from the National Institutes of Health website
  • This procedure can also be performed with a single fluorophore since measurements can be taken sequentially and the first reagent will then be washed out before the second reagent is introduced.
  • Example 2 Determination of heterogeneity of varying ratios of mAbs ‘spiked’ in null CCS (cell culture supernatant)
  • Table 2 Data show that the plate assay can be used to assess the degree of heterogeneity in various CCS samples.
  • Example 3 Fluorescence-based 96-well plate assay to determine the heterogeneity of bispecific antibodies with different architectures.
  • Single cells with the required nucleotide sequences to express a tri-specific molecule are loaded into individual pens, and they are allowed to grow over a period of 4 days by perfusing media into the chip.
  • fluorescently labelled Antigen 1 , Antigen 2 and Antigen 3 antigens are prepared at a concentration >10x Ko of the interaction.
  • Estimation of the clones expressing tri-specifics can be determined by two workflows:
  • Antigens 1 , 2 and 3 labelled with 3 different fluorophores with minimal spectral overlap are prepared to a working concentration of >10x Ko of the interaction.
  • the fluorescently labelled antigens are mixed in equimolar ratios and perfused into the chip. Fluorescence signal from each labelled antigen is collected and the data are used to estimate the ratios of antigen binding sites in molecules secreted by the clones.
  • the multiplexed method can be used only in cases where the antigen binding sites are not within the FRET distance (0.2-0.9nm).
  • Plate based assays can be used to assess the degree of multi-specificity binding using both the sequential as well as the multiplexed approach.
  • the IgG tri-specific is immobilized on a Protein A coated 96-well plate, and the excess molecule washed off the plate using an appropriate buffer.
  • the workflow is similar to the Beacon workflow described above, except that a fluorescence plate reader is used to measure the fluorescence intensity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgation concerne des procédés de criblage de cellules productrices pour des clones qui expriment une proportion élevée de molécules de liaison multispécifiques assemblées correctement.
PCT/EP2023/055345 2022-03-03 2023-03-02 Procédé de sélection de cellules clonales exprimant des molécules de liaison multispécifiques assemblées correctement WO2023166130A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22160066.1A EP4239333A1 (fr) 2022-03-03 2022-03-03 Procédé de sélection de cellules clonales exprimant des molécules de liaison multispécifiques assemblées correctement
EP22160066.1 2022-03-03

Publications (1)

Publication Number Publication Date
WO2023166130A1 true WO2023166130A1 (fr) 2023-09-07

Family

ID=80628978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/055345 WO2023166130A1 (fr) 2022-03-03 2023-03-02 Procédé de sélection de cellules clonales exprimant des molécules de liaison multispécifiques assemblées correctement

Country Status (2)

Country Link
EP (1) EP4239333A1 (fr)
WO (1) WO2023166130A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
CN104818295A (zh) * 2015-02-03 2015-08-05 武汉友芝友生物制药有限公司 制备和筛选表达双特异性抗体细胞株的方法
US9857333B2 (en) 2012-10-31 2018-01-02 Berkeley Lights, Inc. Pens for biological micro-objects
WO2018076024A2 (fr) * 2016-10-23 2018-04-26 Berkeley Lights, Inc. Procédés de criblage de lymphocytes b

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US9857333B2 (en) 2012-10-31 2018-01-02 Berkeley Lights, Inc. Pens for biological micro-objects
CN104818295A (zh) * 2015-02-03 2015-08-05 武汉友芝友生物制药有限公司 制备和筛选表达双特异性抗体细胞株的方法
WO2018076024A2 (fr) * 2016-10-23 2018-04-26 Berkeley Lights, Inc. Procédés de criblage de lymphocytes b

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRATT ET AL., BIOPROCESS INTERNATIONAL, vol. 15, no. 11, 2017, pages 36 - 42
LE ET AL.: "A novel mammalian cell line development platform utilizing nanofluidics and optoelectro positioning technology", BIOTECHNOL PROG, vol. 34, 2018, pages 1438 - 46, XP055914993, DOI: 10.1002/btpr.2690
MOCCIARO ET AL.: "Light-activated cell identification and sorting (lacis) for selection of edited clones on a nanofluidic device", COMMUN BIOL, vol. 1, 2018, pages 41, XP055718236, DOI: 10.1038/s42003-018-0034-6
WINTERS AARON ET AL: "Rapid single B cell antibody discovery using nanopens and structured light", vol. 11, no. 6, 11 June 2019 (2019-06-11), US, pages 1025 - 1035, XP055920304, ISSN: 1942-0862, Retrieved from the Internet <URL:https://tandfonline.com/doi/pdf/10.1080/19420862.2019.1624126> DOI: 10.1080/19420862.2019.1624126 *
XU LIMING ET AL: "Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 2, 16 December 2014 (2014-12-16), pages 463 - 473, XP029196224, ISSN: 1567-5769, DOI: 10.1016/J.INTIMP.2014.12.011 *

Also Published As

Publication number Publication date
EP4239333A1 (fr) 2023-09-06

Similar Documents

Publication Publication Date Title
Emanuel et al. Recombinant antibodies: a new reagent for biological agent detection
CN106047857A (zh) 一种发掘特异性功能抗体的方法
US20170088611A1 (en) Single-chain multivalent binding protein compositions and methods
US20230341381A1 (en) Methods and reagents for determining immunoglobulin gamma (IgG) antibody isotype concentration from biological samples
CN107064092B (zh) 一种双特异性抗体生物学活性与滴度检测方法及其应用
Ayoubi et al. A consensus platform for antibody characterization
JP5380303B2 (ja) 高分子アディポネクチン測定法
EP4239333A1 (fr) Procédé de sélection de cellules clonales exprimant des molécules de liaison multispécifiques assemblées correctement
Sakaguchi et al. Rapid, simple, and effective strategy to produce monoclonal antibodies targeting protein structures using hybridoma technology
CA2977436C (fr) Procede et systeme de detection d&#39;anticorps
KR20240155231A (ko) 정확하게 조립된 다중특이적 결합 분자를 발현하는 클론성 세포를 선택하는 방법
Miller et al. Epitope binning of murine monoclonal antibodies by a multiplexed pairing assay
CN118829880A (zh) 选择表达正确组装的多特异性结合分子的克隆细胞的方法
CN107924164A (zh) 定量的基于fret的相互作用测定
Campbell et al. Chimeric Protein Switch Biosensors
US11913951B2 (en) High throughput method for measuring the protease activity of complement C3 convertase
US20190369095A1 (en) Novel antibody for determination of adamts-13 activity
Anaya Modernization of monoclonal antibody screening and protein-interaction assays
Sádio et al. Yeast surface display and cell sorting of antigen-binding Fc fragments
US20160349270A1 (en) Flip (fluorescence immunoprecipitation) for high-throughput immunoprecipitation
US20050208586A1 (en) Using complement component C1q derived molecules as tracers for fluorescence polarization assays
Bahadır Developing selection strategy for CHO-K1 cell line that secretes scfv-Fc fusion antibodies using ClonePix2
Sakaguchi et al. Rapid, simple, and effective strategy to produce monoclonal antibodies targeting native protein structures using hybridoma technology
Omidfar et al. A mini review on recent progress of microfluidic systems for antibody development
Challa et al. Function-first discovery of high affinity monoclonal antibodies using Nanovial-based plasma B cell screening

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23707421

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 315422

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2023707421

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2023707421

Country of ref document: EP

Effective date: 20241004